Abstract
In vitro anticancer drug sensitivity tests have been performed for various types of cancers, and a relationship with clinical response has been observed. The collagen gel droplet-embedded culture drug sensitivity test (CD-DST) is a new in vitro anticancer drug sensitivity test by Yabushita et al., recently reported to be useful in ovarian cancer. CD-DST allows analysis of a small number of cells, compared to other anticancer drug sensitivity tests. Here, we report a successful analysis of anticancer drug sensitivity by CD-DST using cancerous ascites and pleural fluid samples from 2 patients with advanced ovarian cancer. To our knowledge, this is only the second report of the application of CD-DST in ovarian cancer, and our results suggest that CD-DST could be helpful in the selection of anticancer drugs for neoadjuvant chemotherapy in advanced ovarian cancer.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Ascites / pathology
-
Camptothecin / administration & dosage
-
Camptothecin / analogs & derivatives
-
Camptothecin / pharmacology
-
Cisplatin / administration & dosage
-
Cisplatin / pharmacology
-
Docetaxel
-
Doxorubicin / administration & dosage
-
Doxorubicin / pharmacology
-
Drug Screening Assays, Antitumor / methods*
-
Female
-
Humans
-
Irinotecan
-
Middle Aged
-
Neoplasm Recurrence, Local / drug therapy
-
Neoplasm Recurrence, Local / pathology
-
Ovarian Neoplasms / drug therapy*
-
Ovarian Neoplasms / pathology*
-
Paclitaxel / administration & dosage
-
Paclitaxel / pharmacology
-
Pleural Effusion, Malignant / pathology
-
Taxoids / administration & dosage
-
Taxoids / pharmacology
Substances
-
Taxoids
-
Docetaxel
-
Irinotecan
-
Doxorubicin
-
Paclitaxel
-
Cisplatin
-
Camptothecin